• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Over $13M Bet On This Energy Stock? Check Out These 4 Stocks Insiders Are Buying

    11/10/23 8:52:06 AM ET
    $AURA
    $ET
    $MA
    $STAA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Natural Gas Distribution
    Public Utilities
    Get the next $AURA alert in real time by email

    Although U.S. stocks closed lower on Thursday, there were a few notable insider trades.

    When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

    Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

    Aura Biosciences

    • The Trade: Aura Biosciences, Inc. (NASDAQ:AURA) 10% owner David Goel acquired a total of 1,560,000 shares an average price of $9.00. To acquire these shares, it cost around $14.04 million. The company’s Director also bought 199,601 shares.
    • What’s Happening: Aura Biosciences posted a narrower-than-expected loss for the third quarter.
    • What Aura Biosciences Does: Aura Biosciences Inc is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system to create long-lasting anti-tumor immunity.
    • Mastercard

    • The Trade: Mastercard Incorporated (NYSE:MA) Director Richard K Davis acquired a total of 1,000 shares at an average price of $390.96. To acquire these shares, it cost around $390,960.
    • What’s Happening: Mastercard reported better-than-expected earnings for its third quarter.
    • What Mastercard Does: Mastercard is the second-largest payment processor in the world, having processed close to over $8 trillion in transactions during 2022.

    Don’t forget to check out our premarket coverage here

    STAAR Surgical

    • The Trade: STAAR Surgical Company (NASDAQ:STAA) 10% owner Broadwood Capital Inc bought a total of 289,140 shares at an average price of $33.42. To acquire these shares, it cost around $9.66 million.
    • What’s Happening: Staar Surgical reported better-than-expected earnings for its third quarter.
    • What STAAR Surgical Does: Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye.

    Energy Transfer

    • The Trade: Energy Transfer LP (NYSE:ET) Executive Chairman Kelcy Warren bought a total of 1,000,000 shares at an average price of $13.33. The insider spent around $13.33 million to buy those shares. The company’s EVP also bought 10,000 shares.
    • What’s Happening: Energy Transfer posted downbeat earnings for the third quarter.
    • What Energy Transfer Does: Energy Transfer owns a large platform of crude oil, natural gas, and natural gas liquid assets primarily in Texas and the U.S. midcontinent region.

     

    Check This Out: Top 2 Materials Stocks You May Want To Dump This Quarter

    Get the next $AURA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AURA
    $ET
    $MA
    $STAA

    CompanyDatePrice TargetRatingAnalyst
    Mastercard Incorporated
    $MA
    3/31/2026$631.00Buy
    Loop Capital
    Energy Transfer L.P.
    $ET
    3/24/2026$23.00Buy
    Truist
    Mastercard Incorporated
    $MA
    3/19/2026$600.00Neutral → Outperform
    BNP Paribas Exane
    Mastercard Incorporated
    $MA
    3/5/2026$700.00Buy
    BofA Securities
    Energy Transfer L.P.
    $ET
    2/18/2026$20.00 → $21.00Buy
    TD Cowen
    STAAR Surgical Company
    $STAA
    2/3/2026$26.00Neutral
    Wedbush
    Mastercard Incorporated
    $MA
    2/3/2026$610.00Neutral → Outperform
    Daiwa Securities
    Mastercard Incorporated
    $MA
    1/27/2026$650.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $AURA
    $ET
    $MA
    $STAA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Interim Co-CEO and Pres. & COO Foust Warren converted options into 37,500 shares, increasing direct ownership by 144% to 63,588 units (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    3/16/26 5:00:16 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by Interim Co-CEO and CFO Andrews Deborah J

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    3/16/26 5:00:17 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Chief Development Officer Michna Magda converted options into 23,773 shares and covered exercise/tax liability with 8,529 shares, increasing direct ownership by 105% to 29,668 units (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    3/16/26 5:00:14 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $AURA
    $ET
    $MA
    $STAA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Broadwood Partners, L.P. bought $12,266,545 worth of shares (670,213 units at $18.30) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    3/13/26 7:59:59 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Large owner Broadwood Partners, L.P. bought $606,138 worth of shares (27,485 units at $22.05) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    1/13/26 9:30:12 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Large owner Broadwood Partners, L.P. bought $8,817,664 worth of shares (406,653 units at $21.68) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    1/8/26 7:31:31 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $AURA
    $ET
    $MA
    $STAA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Small Businesses Can Soon Enjoy New Rewards With the Prime Business and Amazon Business Credit Cards

    Amazon is transitioning its small business credit cards to U.S. Bank and Mastercard, with more benefits, tools, and features than ever before Amazon (AMZN) today announced a new Prime Business Card and a new Amazon Business Card, coming this spring, offering U.S. customers more ways than ever to save along with a suite of new features designed for small business customers. The cards will be issued by U.S. Bank (USB) as part of the Mastercard (MA) network. Customers can choose between two options: the Prime Business Card, offering Prime members 5% back on Amazon purchases, or the Amazon Business Card, offering 3% back for customers without a Prime membership*. Both versions of the card o

    3/31/26 9:00:00 AM ET
    $AMZN
    $MA
    $USB
    Catalog/Specialty Distribution
    Consumer Discretionary
    Real Estate
    Major Banks

    Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

    Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance Phase 1b/2 NMIBC Trial on Track: Initial 3-Month Clinical Data Expected Mid-2026 12-month Stability Completed with New Formulation with Potential Across Non-ocular Solid Tumor Indications, Beginning with Urologic Oncology BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided recent business highlights. "2025 has been a year

    3/30/26 7:00:00 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Threat Hunting Revolution Accelerates with Rapid Adoption of Recorded Future's Autonomous Threat Operations (ATO)

    ATO Users Detect and Eradicate Adversaries with Autonomous Intelligence-Driven Threat HuntingSAN FRANCISCO, March 24, 2026 /PRNewswire/ -- On the eve of RSA 2026, Recorded Future reported strong growth in the adoption of Autonomous Threat Operations (ATO), a revolutionary capability that gives defenders the tools they need to detect and eradicate adversaries in the cyber domain, turning real-time threat intelligence into continuous threat hunts across heterogeneous environments. In the first month of general availability, Recorded Future's ATO users have radically expanded their

    3/24/26 10:00:00 AM ET
    $MA
    Real Estate

    $AURA
    $ET
    $MA
    $STAA
    SEC Filings

    View All

    SEC Form S-8 filed by Aura Biosciences Inc.

    S-8 - Aura Biosciences, Inc. (0001501796) (Filer)

    3/30/26 7:27:38 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Aura Biosciences Inc.

    10-K - Aura Biosciences, Inc. (0001501796) (Filer)

    3/30/26 7:15:29 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aura Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Aura Biosciences, Inc. (0001501796) (Filer)

    3/30/26 7:05:19 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AURA
    $ET
    $MA
    $STAA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Loop Capital initiated coverage on Mastercard with a new price target

    Loop Capital initiated coverage of Mastercard with a rating of Buy and set a new price target of $631.00

    3/31/26 8:15:00 AM ET
    $MA
    Real Estate

    Truist initiated coverage on Energy Transfer with a new price target

    Truist initiated coverage of Energy Transfer with a rating of Buy and set a new price target of $23.00

    3/24/26 8:38:40 AM ET
    $ET
    Natural Gas Distribution
    Public Utilities

    Mastercard upgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane upgraded Mastercard from Neutral to Outperform and set a new price target of $600.00

    3/19/26 8:23:09 AM ET
    $MA
    Real Estate

    $AURA
    $ET
    $MA
    $STAA
    Leadership Updates

    Live Leadership Updates

    View All

    Mastercard reinforces commitment to Canadian small business owners as the Mastercard Small Business Fund opens for 2026 applicants

    Mastercard invites women small business owners in Canada to apply for one of ten grants of $10,000 CAD each, access to mentorship, and resources to support their business growth.TORONTO, March 3, 2026 /CNW/ - Today, Mastercard opens applications for the Mastercard Small Business Fund, giving women small business owners in Canada the opportunity to receive a $10,000 CAD grant and resources to equip their business for future growth. Along with funding, grant recipients will receive tailored mentorship, support for growing their business digitally, and a Priceless Experience in Toronto.

    3/3/26 9:00:00 AM ET
    $MA
    Real Estate

    STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs

    Search Committee Has Initiated a Global Search to Select Next CEO STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors (the "Board") has appointed Warren Foust, President and Chief Operating Officer, and Deborah Andrews, Chief Financial Officer, as interim co-Chief Executive Officers, effective February 1, 2026. Mr. Foust and Ms. Andrews will work together with the other members of the executive leadership team, with support and guidance from the Board, as they lead the Company and manage its day-to-day operations.

    2/2/26 7:00:00 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement

    Neal Bradsher and Richard LeBuhn of Broadwood and Christopher Wang of Yunqi Capital have Joined STAAR Board STAAR Chair Elizabeth Yeu and CEO Stephen Farrell have Stepped Down from the Board Farrell will Remain CEO until January 31, 2026 STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, and Broadwood Partners, L.P. and its affiliates ("Broadwood"), which together own 31% of STAAR's outstanding common stock, today announced that Neal C. Bradsher and Richard T. LeBuhn of Broadwood and Christopher Wang of Yunqi Capital, which with its affiliates owns 6.5%

    1/15/26 8:30:00 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $AURA
    $ET
    $MA
    $STAA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aura Biosciences Inc.

    SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)

    11/14/24 5:50:51 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aura Biosciences Inc.

    SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)

    11/14/24 4:18:22 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aura Biosciences Inc.

    SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)

    11/12/24 9:32:49 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AURA
    $ET
    $MA
    $STAA
    Financials

    Live finance-specific insights

    View All

    Mastercard to Acquire BVNK to Connect On-Chain Payments and Fiat Rails

    Expands capabilities to support greater choice in how people and businesses exchange value BVNK's digital asset infrastructure complements and extends Mastercard's trusted global payments network, creating interoperability between fiat and stablecoins Enables financial institutions and other customers to address new use cases with stablecoins, tokenized deposits and tokenized assets Mastercard today announced a definitive agreement to acquire BVNK, a leader in stablecoin infrastructure, for up to $1.8 billion, including $300 million in contingent payments. The deal further expands Mastercard's end-to-end support of digital assets and value movement across currencies, rails and reg

    3/17/26 8:00:00 AM ET
    $MA
    Real Estate

    STAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 Results

    Confident in China Progress and Future Roadmap A Clear Path Toward Sustainable Profitability and Growth Board and Leadership Transitions Support Strategy Execution and Shareholder Value Creation STAAR Interim co-CEOs Issue Letter to Shareholders Earnings Call and Webcast Today at 5:30 PM Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the fourth quarter and fiscal year ended January 2, 2026. STAAR's Interim co-CEOs will be issuing a Letter to Shareholders after this earnings release, which can be found here: https://investors.staar.com/new

    3/3/26 4:01:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical to Host Fourth Quarter and Fiscal Year 2025 Earnings Conference Call and Webcast on March 3, 2026

    STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the fourth quarter and fiscal year ended January 2, 2026, on Tuesday, March 3 after the market close. The Company will also host an earnings call and webcast at 5:30 p.m. ET to discuss its financial results and business progress. Event: STAAR Surgical Fourth Quarter and Fiscal Year 2025 Financial Results Webcast Date: Tuesday, March 3, 2026 Time: 5:30 p.m. ET/ 2:30 p.m. PT Location: https://event.choruscall.com/mediaframe/webcast.html?webcastid=J3bNAuVd Topics on the c

    2/23/26 4:01:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care